Navigation Links
Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
Date:4/4/2011

asing heart rate.  However, unlike SNP, CXL-1020 also showed significantly improved heart muscle contraction (inotropy) and relaxation (lusitropy). Moreover, study findings reported that the effects of CXL-1020 were independent from Beta-Adrenergic Receptor and ACE-inhibitor pathways.  Compared to the inotrope dobutamine , CXL-1020 significantly reduced after-load, stroke work and energetic demand, demonstrating its unique, energetically favorable profile.  The researchers conclude that CXL-1020, through its unique mechanism of action, improves heart function in a manner distinct from nitrovasodilators, and that its efficacy will not be reduced with either beta-blockers or ACE inhibitors, medicines commonly prescribed for patients with heart failure.

A Phase I/IIa First in Man Safety and Tolerability Study of a Novel HNO Donor, CXL-1020, in Patients with Stable Congestive Heart Failure. Monday, April 4, 2011; 9:30 a.m. – 12:30 p.m., Ernest N. Morial Convention Center, Hall F; Poster Board #42

The data presented in this poster demonstrates the safety and tolerability of the novel treatment, CXL-1020, in stable congestive heart failure (CHF) patients.  In the double-blind, placebo controlled, randomized, dose escalation study, two cohorts of patients received four sequentially increasing four-hour infusions, at half-log dose increments between 0.1-30 microgram/kg/min with a randomly interspersed placebo. Patient safety was monitored throughout the study. Researchers also evaluated the plasma and urine pharmacokinetics (PK) during treatment and up to 24 hours post dosing.  The results show that CXL-1020 was well tolerated at doses up to 10 microgram/kg/min with no significant change in heart rate or systolic blood pressure, no decrease in kidney function, and no increase in ventricular ectopy.  The PK of CXL-1020 and its by-product were dose-proportional, and greater than 90 percent of the by-product was recovere
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... -- Edwards Lifesciences Corporation (NYSE: EW ), the global ... monitoring, today reported net income for the quarter ended ... share.  Net income for the same period a year ... and non-GAAP net income was $82.1 million, or $0.76 ... quarter ended March 31, 2015 increased 13.0 percent to $590.3 ...
(Date:4/23/2015)... DUBLIN , April 23, 2015  Jazz Pharmaceuticals ... will report its 2015 first quarter financial results on ... financial markets.  Company management will host a live audio ... p.m. IST to discuss first quarter 2015 financial results ... Interested parties may access the live audio webcast via ...
(Date:4/23/2015)... , April 23, 2015  DanDrit Biotech A/S ... USA , Inc. ("DanDrit"), (symbol : ... approved vaccine for the treatment of colorectal cancer, ... Pharma have signed a partnership agreement in ... collaboration agreement advances DanDrit,s goal to deliver an ...
Breaking Medicine Technology:Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2DanDrit Biotech and Riyadh Pharma Sign Partnership Agreement 2
... Corp. (Nasdaq: BSTC ; the "Company" or ... products, today announced that its Board of Directors has ... 14, 2002 and previously amended June 19, 2003 (the ... for determining "Acquiring Person" status under the Rights Agreement ...
... Feb. 7, 2011 Cancer ... served by just 11 modern radiotherapy linear accelerators, now ... Systems (NYSE: VAR). Treatments using fast and efficient RapidArc® ... Clinac® iX medical linear accelerator at the new United ...
Cached Medicine Technology:Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems 2Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems 3
(Date:4/25/2015)... Sports controversies continue to revolve around issues of ... the case with the Miami Dolphins and Richie Incognito, or off ... Ray Rice domestic abuse case. In a recent episode of ... the implications of locker room culture on teams. He examines what ... should do to improve the locker room as a work place. ...
(Date:4/24/2015)... 24, 2015 Multi Customer Discount , ... pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 gallons in Zeiter's ... program. This does not include any Dig fees, or ... per person. If someone is part of this group ... totaling approximately 2500 gallons or more, the cost would ...
(Date:4/24/2015)... April 24, 2015 Lipitor lawsuits ... in the federal multidistrict litigation underway in U.S. ... court documents, the parties involved in the proceeding ... detailing, among other things, preparation for the litigation’s ... for both plaintiffs and defendants have conducted depositions ...
(Date:4/24/2015)... 2015 Carinsurancequotesinfo.com has released a new ... how to qualify for auto insurance as ... for auto insurance online, without having to follow a ... single parents can reduce their auto insurance expenses. The ... properly explained. , Clients can now visit an ...
(Date:4/24/2015)... With years of experience providing ... proud to be partnered with a veterinary college where ... year. This partnership has brought new payment options for ... After providing an in-house payment plan for many years, ... wanted to increase financing options available to avoid having ...
Breaking Medicine News(10 mins):Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2
... are calling for greater clarity on the legal implications of ... that this is often done following staff needlestick injuries, in ... the September issue of Anaesthesia , reports on the ... England, Wales and Northern Ireland. It is accompanied by ...
... rapidly, the University of Missouri has made a commitment to ... community and across the country. MU was one of ... Difficult Dialogues Initiative (DDI) in 2005, and one of only ... additional $100,000 grant in 2008. DDI activities focus on teaching ...
... , MONDAY, Aug. 30 (HealthDay News) -- The rate of ... steps are needed to reverse the trend, a new study ... delivery climbed by more than 50 percent, and "one in ... lead researcher Dr. Jun Zhang, of the Eunice Kennedy Shriver ...
... with acute coronary syndromes initially treated with the anticoagulant ... angioplasty) and received a lower dose of the anticoagulant ... rate of major bleeding and vascular access site complications, ... September 22 issue of JAMA . The study ...
... University, has found that lower doses of a ... did not reduce bleeding or vascular complications compared ... with a blood thinner, fondaparinux. In a ... McMaster University showed that a blood thinner fondaparinux ...
... -- The incidence of acute myocardial infarction in Italy ... 2001 and 2005, according to a comprehensive study funded ... charity for biomedical research and health education in Spoleto, ... Experimental Research . "The study suggests that more information ...
Cached Medicine News:Health News:Hospitals face legal dilemma if they test incapacitated patients after needle accidents 2Health News:Hospitals face legal dilemma if they test incapacitated patients after needle accidents 3Health News:Hospitals face legal dilemma if they test incapacitated patients after needle accidents 4Health News:Difficult Dialogues Initiative promotes diversity at MU, around country 2Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 2Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 3Health News:Almost 1 in 3 First-Time Deliveries Now Via C-Section 4Health News:Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding 2Health News:Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding 3Health News:Drug trial results refine treatment during angioplasty operations 2Health News:Drug trial results refine treatment during angioplasty operations 3Health News:Heart attacks jump in young Italian women 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: